" class="no-js "lang="en-US"> New Option to Treat Advanced Oesophageal Cancer Approved for NHS in Scotland - Medtech Alert
Thursday, February 09, 2023

New Option to Treat Advanced Oesophageal Cancer Approved for NHS in Scotland

The Scottish Medicines Consortium (SMC) has approved the immunotherapy drug nivolumab (Opdivo) for patients with a type of advanced oesophageal cancer – cancer that forms in the tube that connects the mouth to the stomach – who have previously received chemotherapy.

Nivolumab is the first targeted immunotherapy treatment for people with this type of oesophageal cancer. It also causes fewer side effects than chemotherapy.

David Ferguson, public affairs manager for Cancer Research UK in Scotland, said: “We’re delighted that nivolumab has been approved to treat metastatic oesophageal cancer in Scotland. Cancer Research UK has previously funded clinical trials for this drug and it is a huge step forward for patients and their families.

“We hope that this approval will give patients facing this advanced form of cancer better options for treatment, as well as the chance for more precious time with loved ones.”

The news follows the approval of nivolumab for the same cancer type by the National Institute for Health and Care Excellence (NICE) in England in June, as well as for the treatment for a type of advanced bowel cancer in combination with the drug ipilimumab (Yervoy).

A needed treatment for an aggressive cancer

Nivolumab is a type of immunotherapy that blocks a protein that stops the immune system from locating and attacking cancer cells.

“This drug is the first of its kind to be offered to patients with metastatic oesophageal cancer. Nivolumab provides a more targeted approach to treating cancer, by helping the immune system to attack tumours,” said Ferguson.

Treatment options for advanced oesophageal squamous cell carcinoma have been very limited – those who are fit enough are offered further chemotherapy, but the benefit is small and side effects are rife, leading to hospital admission, impact on quality of life and poor prognosis.

In the Patient and Clinician Engagement (PACE) meeting ahead of the decision, patients spoke about how this type of cancer can be severe and debilitating, often with short life expectancy. They described their experiences of having difficulty swallowing, as well as vomiting, pain and general deterioration in health, which often progresses rapidly over just a few months.

This has a major impact on their quality of life, as well as their carers and families.

In Scotland, nivolumab will now be available to treat adult patients with oesophageal squamous cell carcinoma that cannot be removed by surgery and has either come back or spread to other parts of the body after initially being treated with chemotherapy.

Companies In This Post

  1. ReviR Therapeutics and Asieris Pharmaceuticals Enter into Agreement to Discover Oncology Therapeutics Read more
  2. Superior HealthPlan and eFamilyCare Expand Partnership to Support Medicaid Members and Caregivers in Texas Read more
  3. Garuda Therapeutics Secures $62 Million Series B Financing to Advance Off-the-Shelf Blood Stem Cell Technology Platform Read more
  4. FSD Pharma Receives Regulatory Clearance for Its Proposed Phase-1 Clinical Trial of Lucid-21-302 (Lucid-MS), First-in-Class Multiple Sclerosis Drug Candidate Read more
  5. $25 Million Gift to Penn Medicine and Children’s Hospital of Philadelphia Establishes Center for Epilepsy and Neurodevelopmental Disorders Read more